

Disclosures

Personal Commercial (17)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------------------|--|--------------------------|------------------------------------|
| <i>Self</i> | | | |
| Agitated Saline Solutions | Data Safety Monitoring Board | Modest (< \$5,000) | Noninvasive Imaging |
| Anumana | Research/Research Grants ‡ A Multicenter Study of Detection of Pulmonary Hypertension Based on Point-Of-Care 12-Lead ECG Data | Significant (>= \$5,000) | Noninvasive Imaging |
| Bracco Diagnostics | Research/Research Grants ‡ Not applicable | Significant (>= \$5,000) | Noninvasive Imaging |
| Bracco Diagnostics | Consultant Fees/Honoraria | Modest (< \$5,000) | Noninvasive Imaging |
| Bristol Myers Squibb | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| EchoIQ | Research/Research Grants ‡ Not Applicable | Significant (>= \$5,000) | Noninvasive Imaging |
| EchoIQ | Other - Scientific Advisory Board | Significant (>= \$5,000) | Noninvasive Imaging |
| Edwards Lifesciences | Consultant Fees/Honoraria | Significant (>= \$5,000) | Valvular Heart Disease |
| Edwards Lifesciences | Research/Research Grants ‡ Not applicable | Significant (>= \$5,000) | Valvular Heart Disease |
| EVERSANA Lifesciences | Research/Research Grants ‡ Post Marketing Observational Study on Safety of BALFAXAR® vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure | Significant (>= \$5,000) | Other |
| EVERSANA Lifesciences | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |
| General Electric Healthcare | Consultant Fees/Honoraria | Modest (< \$5,000) | Noninvasive Imaging |
| HeartSciences | Other - Scientific Advisory Board | Significant (>= \$5,000) | Noninvasive Imaging |
| Philips Healthcare | Research/Research Grants ‡ Philips Ultrasound Study Protocol - Beth Israel Deaconess Medical Center | Significant (>= \$5,000) | Noninvasive Imaging |
| Philips Healthcare | Consultant Fees/Honoraria | Modest (< \$5,000) | Noninvasive Imaging |
| Ultrasight | Consultant Fees/Honoraria | Modest (< \$5,000) | Noninvasive Imaging |
| Viz.ai | Research/Research Grants ‡ Not applicable | Significant (>= \$5,000) | Arrhythmias and Clinical EP |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|--|--------------------------|------------------------|
| <i>Self</i> | | | |
| NIH/NHLBI ‡ none | Research/Research Grants | Significant (>= \$5,000) | Noninvasive Imaging |
| NIH/NHLBI | Research/Research Grants ‡ Chronic Renal Insufficiency and Silent Progression of Aortic Stenosis (CRISP-AS) Study | Significant (>= \$5,000) | Valvular Heart Disease |

Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|----------------|---------------|----------------------|
| EXPAND TAVR II | MEDTRONIC | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|-------------|--|---------------------------|--|--------------------------|
| <i>Self</i> | | | | |
| 2025 | Noninvasive Imaging - Ultrasound Contrast Safety | Defendant † Lawfirm | I am expert witness to a defendant who is accused of malpractice after administering an ultrasound contrast agent in which harm occurred to the patient. | Significant (>= \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/26/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/26/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 2/26/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 2/26/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.